Activity of high-dose cis-platinum (NCI 119875) in combination with vincristine and methotrexate in drug-resistant gestational choriocarcinoma. A report of 17 cases. by Newlands, E. S. & Bagshawe, K. D.
Br. J. Cancei, (19.79) 40,9-43
Short Communication
ACTIVITY OF HIGH-DOSE CIS-PLATINUM (NCI 119875)
IN COMBINATION WITH VINCRISTINE AND METHOTREXATE
IN DRUG-RESISTANT GESTATIONAL CHORIOCARCINOMA.
A REPORT OF 17 CASES
E. S. NENN'LANDS AND K. D. BAGSHANVE
Fram the Departmenl c.f Medical Oncology, Chat-iti-y Cross Ho8pital, Fulhani, Palace Road, Landon TV6
Received 23 July 19719
GESTAT10NIAL CHORIOCARClNOMA -,6th
adverse prognostic factors (Bagshawe,
1976) has frequently proved resistant to
methotrexate. However, with the intro-
duction of drug combinations including
methotrexate, vineristine, actinomycin 1),
cyclophosphamide, adriamycin, mel-
phalan, 6-mereaptopurine and hydroxy-
urea, the incidence of disease resisting
eradication has fallen to -5% of cases
treated at this Centre (Bagshawe, 1977).
Since 1976, we have treated 17 cases of
gestational choriocarcinoma whicli were
resistant to eradication bv these drugs
with high-dose 68-platinum. All patients
hadpreviously received extensivetherapy.
All therapy was monitored bv twice-
weekly radioimmunoassays specific for
human chorionic gonadotrophin (hCGP).
This assay can detect, down to 2 miu/ml
(about equal to 1. ng/ml hCGg in sertim)
(Kardana & Bagshawe, 1976).
68-Platinum is a new anti-cancer agent
which has recently been extensively in-
vestigated in man (Rozeiicweig et al.,
1977; Prestayko et al., 1979). As far as we
are aware, the onlv preliminary reports of
the use of ci-8-platinum in gestational
choriocarcinoma are from this Centre
(Newlands, 1978) and from Amiel et al.
(1978). 63-Platinum. was provided by the
National Cancer Institute, Bethesda, and
was used in a dose of 120 Mg/M2 j.V. with
intense hydration. The hydration was
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based on the work of Hayes et al. (1977).
Mannitol was given in a dose of 10g
hourly for each of 6 h. One litre of i.v.
fluids (alternating normal saline with 5%
dextrose, each containing I g of KCI)
NNI'as given hourly for 3h before the
ci-s-platinum (whiel'i was given as a short
i.v. infusion) and i.v. fluids were continued
at, a rate of I litrehourly for a further 3 h.
Hydration was continued until all vomit-
ing had stopped. All patients were moni-
tored throughout the intense hydration
on a weigh-bed to avoid any fluid over-
load. Most patients received 68-platinum
in combination with vincristine andmetho-
trexate. In this schedule, vineristine was
given in a dose of 1.0 Mg/M2 at 1.0:00
on Day 1, and methotrexate loo Mg/M2
i.v. push at 3.00 p.m. followed by metho-
trexate 200 Mg/M2 over the next 12 h by
i.v. inftision. Folinic acid rescue was star-
ted in a dose of 15 mg i.m. 24 h after the
start of the methotrexate and continued
12-hourly for a ftirther 3 doses. 68-
Platinum was given as described above on
Day 4. With the known nephrotoxicity of
high-dose methotrexate it was considered
unwise to give a second nephrotoxic drug,
68-platinum, until the methotrexate had
been excreted, soci-s-platinum wasdelayed
untilDay 4. During aseparatepilotevalua-
tion with cis-platinum, 2 patients (one
with malignant teratoma and one with
choriocarcinoma) had responded to ci8-944 E. S. NEWLANDS AND K. 1). BAGSHAWE
platinum in combination with vineristine
and methotrexate, whereas no response
had been seen with cis-platinum alone. All
patients hadpreviously received on several
occasions vineristine and methotrexate in
the identical schedule to that used in the
63-platinum combination. Resistance had
been demonstrated in all patients to
vineristine and methotrexate when, com-
bined with hydroxyurea, cyclophospha-
mide, actinomycin D, adriamycin and
melphalan in a 7-drug regimen (Bag-
shawe, 1977).
The toxicity0f68-platinum in this dose
of I2OMg/M2 alone, and in combination
with vincristine and methotrexate, was
manageable. Only one patient at the start
of the series had major renal impairment,
which recovered over the next few months.
This was thought to be due to the ci,3-
platinum being given before the full
diuresis was under way, and the timing
of the 68-platinum was put back to the
end of the first 3 h of hydration. All
patients experienced nausea andvomiting
lasting in most cases for 12-24 h, which
was only partially controlled with anti-
emeties. Myelosuppression affectino,
haemoglobin, white blood counts and
platelet counts occurred in some patients,
but this recovered during the subsequent
2-3 weeks. No mucositis was seen. Routine
audiograms showed some impairment in
high-frequency hearing in many of the
patients, but only one patient experienced
sufficienthearing loss for this to be socially
noticeable.
The definition of response in chorio-
carcinoma differs from the conventional
solid-tumour criteria, since there is a
more accurate biochemical monitor of the
disease in the hCG concentration, and in
only some patients were there measurable
pulmonary secondaries to provide linear
measurements of disease activity. In
these 17 patients, and in the large experi-
ence of this Centre (over 500 patients
treated up to 1978), the clinical and
radiological evidence of disease activity
correlates very accurately with the hCG
concentrations, but these responses are
slower than the biochemical chaiiges.
Responses in the 17 patients were defined
as:
A response was a > I log fall in the serum
hCGP concentration after a single course
of therapy with cis-platinum, and before
the next course ofchemotherapy.
An improvement was a >50% fall in
hCGP concentration after a single course
oftherapy.
Progressive disease was a rising hCGg
value after a course of chemotherapy.
The results with the 17 patients are
summarized in the Table. The patients'
ages ranged from 20 to 0-3 years and the
TABLE.-Re-SUlt-8 icith high-dose cis-
platinum in choriocarcinonta. May 1.979
(I7patients)
Progres-
sll%,(,.
disease Improx-e-
ment* Responset
cis-Platintim
alone
Vincristine +
methotrexate +
cis-platinum
21 0 0
3 71 6
* > 50% fall in hCG concentration.
t > 10-fold fall in liCG concentration.
I I patient received botli treatments in sequence.
interval from the antecedent pregnancy
before the start of chemotherapy, ranged
from 2 to 48 months. Initial sites of clinic-
ally and radiologically detectable disease
included lung (13), pelvis (6), liver (3),
brain (2), and kidneys (1). There were 3
patients whose hCCxg titres continued to
fall during the next course of chemo-
therapy. On clinical grounds, the next
course of chemotherapy was not delayed
to confirm a clear-cut response to 63-
platinum given in combination, and these
3 patients have been classified as improve-
ments. They went on to achieve acomplete
remission. Up to the time of analysis (May 1979), 7 patients had died of
choriocarcinoma and 4 patients are on
treatment (one patient has developed
acute myeloid leukaemia while in remis-
sion from her choriocarcinoma). SixCIS-PLATINUM COMBINATIONS FOR CHORIOCARCINOMA 945
patients are in complete remission and off
treatment (range 10-25 months).
In summary, 17 patients with drug-
resistantgestational choriocareinoma were
treated with high-dose (12OMg/M2) CiS_
platinum. No activity was seen in 2
patients withhigh-dosecis-platinumalone,
but in combination with vineristine and
methotrexate there were 6 responses and
7improvements, whilstonly 3patients had
progressive disease. cis-Platinum used in
this combination is clearly active, and
requires further assessment in drug-
resistant gestational choriocarcinoma.
We would like to thank the National Cancer
Institute, Bethesda, U.S.A., for supplying us with
cis-platinum for this study.
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